Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 250 IN PLASTIC CONTAINER versus IOPAMIDOL 300 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 250 IN PLASTIC CONTAINER versus IOPAMIDOL 300 IN PLASTIC CONTAINER.
IOPAMIDOL-250 IN PLASTIC CONTAINER vs IOPAMIDOL-300 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiographic contrast medium that attenuates X-rays and provides radiopacity in vascular and body cavities. It does not undergo significant pharmacological activity.
Iopamidol is a non-ionic, low-osmolality iodinated contrast agent that increases the radiopacity of vascular structures and tissues by attenuating X-rays. It distributes into the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
250 mg iodine/mL; 1.5 mL/kg (up to 100 mL) IV bolus or infusion for CT imaging.
Intravenous administration: 1-2 mL/kg (300-600 mg iodine/kg) for contrast imaging; maximum 200 mL per procedure.
None Documented
None Documented
Terminal elimination half-life: 2 hours (normal renal function); prolonged in renal impairment (up to 30+ hours in severe impairment), dictating contrast dosing intervals
Approximately 2 hours in patients with normal renal function (GFR >90 mL/min). Prolonged in renal impairment (up to 30 hours or more in severe disease).
Renal: 95% unchanged via glomerular filtration; biliary/fecal: <5%
Primarily renal via glomerular filtration; >95% eliminated unchanged in urine within 24 hours. Biliary/fecal elimination is negligible (<1%).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent